U87 CAR-T in Patients With Advanced Head and Neck Tumors

This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U87 injection solution in patients with advanced malignant head and neck tumors.

Trial Details

NCT ID
NCT06614686
Phase
PHASE1
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • U87 autologous CAR T-cell
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects have provided informed consent, understanding the study\'s risks and benefits, and are willing to complete the study procedures.
  • Age between 18 and 70 years old at the time of consent, inclusive, and open to both genders.
  • ECOG performance status of 0-1.
  • Anticipated survival of at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →